1. Home
  2. BLKB vs BHVN Comparison

BLKB vs BHVN Comparison

Compare BLKB & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackbaud Inc.

BLKB

Blackbaud Inc.

HOLD

Current Price

$27.91

Market Cap

1.5B

Sector

Technology

ML Signal

HOLD

Logo Biohaven Ltd.

BHVN

Biohaven Ltd.

HOLD

Current Price

$10.75

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLKB
BHVN
Founded
1981
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.4B
IPO Year
2004
2022

Fundamental Metrics

Financial Performance
Metric
BLKB
BHVN
Price
$27.91
$10.75
Analyst Decision
Hold
Buy
Analyst Count
3
14
Target Price
$50.00
$29.08
AVG Volume (30 Days)
624.5K
2.3M
Earning Date
04-29-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
142.32
26.08
EPS
0.67
N/A
Revenue
N/A
N/A
Revenue This Year
$6.26
N/A
Revenue Next Year
$4.25
N/A
P/E Ratio
$45.39
N/A
Revenue Growth
N/A
N/A
52 Week Low
$28.88
$7.48
52 Week High
$74.86
$18.57

Technical Indicators

Market Signals
Indicator
BLKB
BHVN
Relative Strength Index (RSI) 32.30 55.35
Support Level N/A $8.25
Resistance Level $40.38 $11.92
Average True Range (ATR) 1.61 0.85
MACD 0.06 0.17
Stochastic Oscillator 1.64 63.89

Price Performance

Historical Comparison
BLKB
BHVN

About BLKB Blackbaud Inc.

Founded in 1981, Blackbaud provides software solutions designed to serve the "social good" community, including nonprofits, foundations, corporations, educational institutions, healthcare institutions, and individual change agents. Through M&A and organic product development efforts, the company has also moved into related areas outside core fundraising, notably into K-12 schools. The firm enables more than $100 billion in donations annually across a customer base in excess of 40,000 customers in over 100 countries.

About BHVN Biohaven Ltd.

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.

Share on Social Networks: